Acquisition - January 27, 2020
AstraZeneca divests rights to hypertension medicines
AstraZeneca has agreed to sell the global commercial rights to Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma. The agreement excludes the rights in the US and India, which were previously divested, and in Japan, which will be retained by AstraZeneca. The medicines, used primarily to treat hypertension, have lost their patent protection globally. […]
Acquisition - January 14, 2020
Getinge acquires Applikon Biotechnology
Just before Christmas Getinge announced an agreement to acquire 100% of the shares in Applikon Biotechnology. Applikon Biotechnology is a company in the area of advanced bioreactor systems for biopharmaceutical production and research, with an annual net sales of approximately SEK 450 million. “Applikon Biotechnology has a strong portfolio of world class bioreactor solutions which […]
Acquisition - December 20, 2019
AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries
AstraZeneca has agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries1 to Juvisé Pharmaceuticals. The medicines, used primarily to treat breast and prostate cancers, have lost their compound patent protection in these countries. AstraZeneca already divested the rights to both Arimidexand Casodex in the US in […]
Acquisition - November 18, 2019
Recipharm offers to acquire Consort Medical
Recipharm and Consort Medical have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort. The Board of Consort has confirmed its unanimous intention to recommend a cash offer for an equity value of GBP 505 million (approximately SEK 6,284 million). Consort […]
Acquisition - November 11, 2019
Mesa Labs acquires Gyros Protein Technologies
Mesa Laboratories has announced the acquisition of Gyros Protein Technologies Holding AB. GPT is headquartered in Uppsala, Sweden and the acquisition deepens Mesa’s commitment to biopharmaceutical quality control and will be the core of its new platform, Biopharmaceutical Development, it states. GPT was acquired from AP6 (Sixth Swedish National Pension Fund), Ampersand Capital Partners and […]
Acquisition - November 5, 2019
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm. Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia. AstraZeneca will continue […]
